Global Health

1,278.00
+2.60
(0.20%)
Market Cap
34,325.47 Cr
EPS
12.58
PE Ratio
67.54
Dividend Yield
0.00 %
52 Week High
1,511.00
52 Week Low
935.50
PB Ratio
10.91
Debt to Equity
0.55
Sector
Hospitals
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from11 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+63.64 %
+63.64 %
Hold
Hold+18.18 %
+18.18 %
Sell
Sell+18.18 %
+18.18 %
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,076.30
#1 1,04,631.65
98.48
5,584.10
18.77
#1 1,058
-17.46
48.87
7,021.50
1,00,958.40
75.76
#1 19,165.50
14.74
917
49.14
67.35
649.65
49,045.86
64.05
6,931.20
8.99
645
#1 89.49
57.00
1,808.80
36,964.78
45.33
5,093.40
10.96
790
2.66
66.82
1,278.00
#5 34,325.47
#6 67.54
#6 2,759.20
#1 25.09
#6 326
#5 15.71
59.81
644.75
25,798.96
72.52
2,511.20
12.94
336
20.76
59.67
499.05
24,928.20
93.24
3,723.70
22.85
205
-69.22
64.86
1,517.70
15,412.50
66.83
1,334.00
10.76
218
10.06
76.68
5,629.70
13,352.74
#1 29.61
599.90
11.69
58
8.85
53.98
1,437.00
9,421.84
49.27
1,095.50
21.32
177
20.14
38.77
Growth Rate
Revenue Growth
25.09 %
Net Income Growth
66.21 %
Cash Flow Change
107.07 %
ROE
10.63 %
ROCE
12.64 %
EBITDA Margin (Avg.)
10.54 %

Quarterly Financial Results

Quarterly Financials
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
492
588
593
533
627
695
706
732
795
865
855
836
883
975
960
Expenses
386
442
448
441
485
523
534
540
595
631
621
629
675
728
706
EBITDA
106
146
146
92
142
172
172
192
199
234
234
207
208
247
254
Operating Profit %
21 %
24 %
23 %
15 %
21 %
23 %
23 %
24 %
24 %
25 %
26 %
22 %
22 %
24 %
25 %
Depreciation
31
31
33
35
36
37
39
38
40
43
44
46
47
49
49
Interest
16
17
18
28
19
18
21
21
18
20
18
18
18
16
16
Profit Before Tax
58
98
95
29
87
117
112
133
141
171
172
143
144
181
189
Tax
16
31
25
12
28
31
32
32
39
45
49
16
37
50
46
Net Profit
42
67
70
18
59
86
81
101
102
125
124
127
106
131
143
EPS in ₹
5.13
13.22
2.76
0.69
2.32
3.38
3.08
3.77
3.80
4.66
4.61
4.74
3.96
4.87
5.32

Balance Sheet

Balance Sheet
2018
2019
2020
2021
2022
2023
Total Assets
1,984
2,430
2,666
2,694
3,146
4,116
Fixed Assets
1,094
1,194
1,703
1,616
1,776
2,050
Current Assets
472
489
479
502
812
1,580
Capital Work in Progress
317
666
382
464
439
327
Investments
0
0
0
0
0
0
Other Assets
573
570
582
615
930
1,739
Total Liabilities
1,984
2,430
2,666
2,694
3,146
4,116
Current Liabilities
334
296
358
405
420
573
Non Current Liabilities
432
839
959
907
1,110
1,115
Total Equity
1,217
1,296
1,350
1,382
1,616
2,428
Reserve & Surplus
1,136
1,214
1,268
1,300
1,565
2,375
Share Capital
81
49
49
50
51
54

Cash Flow

Cash Flow
2015
2016
2018
2019
2020
2021
2022
2023
Net Cash Flow
-0
-20
3
14
87
-78
50
648
Investing Activities
-126
-241
-69
-249
-87
-239
-421
-342
Operating Activities
213
228
63
166
175
242
311
645
Financing Activities
-88
-7
9
97
-1
-81
160
346

Share Holding

% Holding
Sept 2021
Oct 2022
Nov 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
35.04 %
35.03 %
33.08 %
33.08 %
33.08 %
33.07 %
33.06 %
33.05 %
33.04 %
33.04 %
33.04 %
33.03 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
10.69 %
0.00 %
12.09 %
12.94 %
12.20 %
12.47 %
DIIs
0.00 %
0.00 %
7.78 %
12.55 %
12.35 %
10.80 %
10.93 %
9.68 %
10.25 %
10.57 %
11.11 %
10.51 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
0.00 %
25.44 %
6.16 %
5.77 %
6.79 %
6.85 %
6.79 %
7.14 %
6.28 %
6.54 %
6.74 %
Others
64.96 %
64.97 %
33.69 %
48.21 %
48.80 %
49.34 %
38.48 %
50.48 %
37.47 %
37.16 %
37.10 %
37.24 %
No of Share Holders
47
48
2,86,944
1,21,407
1,07,120
1,09,798
1,16,627
1,24,775
1,66,253
1,55,307
1,49,722
1,48,633

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Announcements

Announcement under Regulation 30 (LODR)-Change in Management1 day ago
Announcement under Regulation 30 (LODR)-Change in Management7 days ago
Announcement under Regulation 30 (LODR)-Meeting Updates8 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20188 days ago
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)8 days ago
Closure of Trading WindowMar 27, 2025
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of AssociationMar 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 22, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 22, 2025
Announcement under Regulation 30 (LODR)-Credit RatingMar 18, 2025
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotMar 17, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 17, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 17, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 01, 2025
Announcement under Regulation 30 (LODR)-Scheme of ArrangementMar 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 21, 2025
Announcement under Regulation 30 (LODR)-Scheme of ArrangementFeb 21, 2025
Announcement under Regulation 30 (LODR)-Scheme of ArrangementFeb 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 15, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 15, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 15, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 12, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 12, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 05, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 05, 2025
Announcement under Regulation 30 (LODR)-Credit RatingFeb 05, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 04, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 04, 2025
Integrated Filing (Financial)Feb 04, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 04, 2025
Announcement under Regulation 30 (LODR)-Meeting UpdatesFeb 04, 2025
Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 For Unaudited Standalone And Consolidated Financial Results Of The Company For The Third Quarter And Nine Months Ended December 3Feb 04, 2025
Unaudited Standalone And Consolidated Financial Results For Third Quarter And Nine Months Ended December 31 2024Feb 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 24, 2025
Announcement under Regulation 30 (LODR)-Credit RatingJan 21, 2025
Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results Of The Company For The Third Quarter And Nine Months Ended December 31 2024.Jan 21, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJan 14, 2025
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderJan 13, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Order Reserved By The Honble National Company Law Tribunal New Delhi BenchJan 08, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 07, 2025
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotDec 28, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportDec 28, 2024
Closure of Trading WindowDec 27, 2024

Technical Indicators

RSI(14)
Neutral
59.81
ATR(14)
Less Volatile
52.13
STOCH(9,6)
Overbought
81.31
STOCH RSI(14)
Neutral
68.79
MACD(12,26)
Bullish
0.78
ADX(14)
Strong Trend
25.26
UO(9)
Bearish
67.71
ROC(12)
Uptrend And Accelerating
2.11
WillR(14)
Overbought
-6.22

About Global Health

Global Health Limited is a private multi-specialty tertiary care provider operating in North and East India. Founded by Dr. Naresh Trehan, the company operates under the Medanta brand with a network of 5 operational hospitals and one under construction. As of June 30, 2022, they offered healthcare services in over 30 medical specialties, employed over 1,300 doctors, and had 2,467 installed beds across 4.7 million sq. ft. of area. The company operates hospitals in Gurugram, Indore, Ranchi, Lucknow, and Patna, with specialties including cardiology, neurosciences, oncology, and orthopedics. Global Health Limited went public in November 2022, raising Rs. 2205.57 crores through an IPO. The company has been expanding its facilities, adding beds, doctors, and new medical equipment across its hospitals.
Listing Date
16 Nov, 2022(2 Years, 31 days)
Chairperson NameNaresh Kumar Trehan